Theophylline 0.16 and dextrose 5% in a plastic container refers to a specific intravenous (IV) drug formulation. This product combines the bronchodilator theophylline with dextrose, a form of sugar used for hydration and calorie supply [1]. It is administered in a plastic bag or container for medical use [1].
What is the purpose of the dextrose in this IV solution?
Dextrose 5% (D5W) is commonly used in intravenous therapy for several reasons. It provides a source of carbohydrates, offering hydration and a small amount of calories. It can also serve as a vehicle for administering other medications, such as theophylline, ensuring they are delivered in a diluted and controlled manner [1].
How is theophylline administered intravenously?
Intravenous administration of theophylline allows for rapid absorption and precise dosing, which is crucial for managing respiratory conditions. The dextrose 5% solution acts as the diluent and carrier for the theophylline. The plastic container is a standard method for sterile IV fluid packaging and delivery [1].
What conditions is intravenous theophylline typically used for?
Intravenous theophylline is primarily used for the short-term management of severe reversible airway obstruction in patients with asthma and other chronic obstructive lung diseases [2]. Its use has declined somewhat with the advent of newer inhaled bronchodilators and corticosteroids, but it remains an option in certain critical situations where other treatments are insufficient [2].
Are there risks associated with intravenous theophylline?
Yes, intravenous theophylline carries a risk of significant side effects, particularly if blood levels are not carefully monitored. Common adverse effects can include nausea, vomiting, headache, insomnia, and tremors. More serious side effects at higher concentrations can involve cardiac arrhythmias, seizures, and even death [2]. Dosing must be adjusted based on individual patient factors like age, weight, and organ function.
How is the correct dose of intravenous theophylline determined?
Determining the correct dose of intravenous theophylline involves careful consideration of the patient's clinical status and often requires therapeutic drug monitoring. Blood levels of theophylline are typically measured to ensure they remain within a safe and effective range, generally between 10 and 20 mcg/mL [2]. This monitoring helps to minimize toxicity while maximizing therapeutic benefit.
What are alternatives to intravenous theophylline?
Current guidelines for managing severe reversible airway obstruction often prioritize inhaled short-acting beta-agonists (SABAs) and systemic corticosteroids as first-line treatments [2]. Other inhaled bronchodilators, such as ipratropium bromide, may also be used. For patients who cannot tolerate or adequately respond to these therapies, intravenous theophylline might be considered as an adjunct [2].
Are there patent considerations for theophylline formulations?
Theophylline has been in use for many decades, and its original patents have long expired. As such, generic formulations of theophylline, including IV solutions, are widely available. DrugPatentWatch.com tracks patents for new drug formulations and delivery systems, but the basic theophylline molecule and standard IV preparations are not subject to current patent protection [3].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.uptodate.com/
[3] https://www.drugpatentwatch.com/